Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation

B McCurdy

June 2013
Suggested Citation

This report should be cited as follows:


Conflict of Interest Statement

All reports prepared by the Division of Evidence Development and Standards at Health Quality Ontario are impartial. There are no competing interests or conflicts of interest to declare.

Disclaimer

This report is the work of the Division of Evidence Development and Standards at Health Quality Ontario, and is developed from expert consultation. Expert consultations are used for interventions for which there is very limited evidence, but consensus by experts on the appropriate use. Health Quality Ontario assumes no responsibility for omissions or incomplete analysis resulting from expert consultations. In addition, it is possible that other relevant scientific findings may have been reported since completion of the report. This report is current to the date of publication, and may be superseded by an updated publication on the same topic. Please check the Health Quality Ontario website for a list of all publications: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations.
About Health Quality Ontario

Health Quality Ontario is an arms-length agency of the Ontario government. It is a partner and leader in transforming Ontario’s health care system so that it can deliver a better experience of care, better outcomes for Ontarians, and better value for money.

Health Quality Ontario strives to promote health care that is supported by the best available scientific evidence. Health Quality Ontario works with clinical experts, scientific collaborators, and field evaluation partners to develop and publish research that evaluates the effectiveness and cost-effectiveness of health technologies and services in Ontario.

Based on the research conducted by Health Quality Ontario and its partners, the Ontario Health Technology Advisory Committee (OHTAC)—a standing advisory subcommittee of the Health Quality Ontario Board—makes recommendations about the uptake, diffusion, distribution, or removal of health interventions to Ontario’s Ministry of Health and Long-Term Care, clinicians, health system leaders, and policy makers.

Rapid reviews, evidence-based analyses and their corresponding OHTAC recommendations, and other associated reports are published on the Health Quality Ontario website. Visit http://www.hqontario.ca for more information.

About Health Quality Ontario Publications

To conduct its rapid reviews, Health Quality Ontario and/or its research partners reviews the available scientific literature, making every effort to consider all relevant national and international research; collaborates with partners across relevant government branches; consults with clinical and other external experts and developers of new health technologies; and solicits any necessary supplemental information.

In addition, Health Quality Ontario collects and analyzes information about how a health intervention fits within current practice and existing treatment alternatives. Details about the diffusion of the intervention into current health care practices in Ontario can add an important dimension to the review. Information concerning the health benefits, economic and human resources, and ethical, regulatory, social, and legal issues relating to the intervention may be included to assist in making timely and relevant decisions to optimize patient outcomes.

Permission Requests

All inquiries regarding permission to reproduce any content in Health Quality Ontario reports should be directed to: EvidenceInfo@hqontario.ca.

How to Obtain Reports From Health Quality Ontario

All rapid reviews are freely available in PDF format at the following URL: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>5</td>
</tr>
<tr>
<td>Objective of Analysis</td>
<td>5</td>
</tr>
<tr>
<td>Clinical Need and Target Population</td>
<td>5</td>
</tr>
<tr>
<td>Ontario Context</td>
<td>5</td>
</tr>
<tr>
<td>Expert Consultation</td>
<td>8</td>
</tr>
<tr>
<td>Research Question</td>
<td>8</td>
</tr>
<tr>
<td>Research Methods</td>
<td>8</td>
</tr>
<tr>
<td>Expert Opinion</td>
<td>8</td>
</tr>
<tr>
<td>Findings</td>
<td>8</td>
</tr>
<tr>
<td>Conclusions</td>
<td>9</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>10</td>
</tr>
</tbody>
</table>
**Background**

Overuse, underuse, and misuse of interventions are important concerns in health care and lead to individuals receiving unnecessary or inappropriate care. In April 2012, under the guidance of the Ontario Health Technology Advisory Committee’s Appropriateness Working Group, Health Quality Ontario (HQO) launched its Appropriateness Initiative. The objective of this initiative is to develop a systematic framework for the ongoing identification, prioritization, and assessment of health interventions in Ontario for which there is possible misuse, overuse, or underuse.

For more information on HQO’s Appropriateness Initiative, visit our website at [www.hqontario.ca](http://www.hqontario.ca).

**Objective of Analysis**

The objective of this analysis is to determine the clinical utility of aspartate aminotransferase (AST) testing in community-based laboratories.

**Clinical Need and Target Population**

Aspartate aminotransferase is an enzyme found in a number of organs and tissues in the body, including the liver, heart, and muscle cells. AST can be measured in the blood stream when one of these organs or tissues is damaged. AST is often used to diagnose or monitor liver damage; however, since it is present in a number of other tissues, it is a relatively non-specific test. There are a number of other liver function tests. One of these tests, alanine aminotransferase (ALT), is more specific than AST.

**Ontario Context**

As shown in Figure 1, between the 2005/2006 and 2010/2011 fiscal years, the number of AST tests performed in Ontario community laboratories dropped substantially—from 4,711,135 to 2,155,220. This was likely caused by the fact that, in August 2007, AST was replaced on the Ontario laboratory requisition form by ALT.
In fiscal year 2011/2012, the top 5 medical specialties that ordered AST tests in community laboratories were:

- Family and general practice (69%)
- Internal medicine (10.1%)
- Rheumatology (5.8%)
- Gastroenterology (2.8%)
- Nurse practitioners (2.5%)

In fiscal year 2011/2012 patients received an average of 1.52 tests (range, 1–71). The breakdown of the amount of repeat testing occurring during this time period is shown in Figure 2.
Data are based on Health care provider claims (excluding out-of-province, out-of-country, and Work Place Safety and Insurance Board claims) in community labs using the Ontario Laboratory Schedule of Benefits fee code L222A (AST) and L223A (ALT). Fiscal service year was defined as having a service date between ccyy-04-01 and ccyy-03-31, assessed to ccyy-09-30 (M7). For example fiscal service year was defined as having a service date between 2003-04-01 and 2004-03-31, assessed to 2004-09-30. The exception is fiscal service year 2011, it is assessed to 2012-06-30 (M4). Data for fiscal year 2011/2012 may not be complete. Ontario registered physicians specialties are allocated based on the physician billing pattern for the applicable fiscal service year. For other health care providers, the practicing specialty allocated to the claim submission number as of the last day of each fiscal year was used.
Expert Consultation

Research Question

What is the clinical utility of AST testing in community-based laboratories?

Research Methods

Expert Opinion

In August 2012, experts were identified to provide advice on the appropriate use of AST testing in the Ontario health care setting. However, the statements, conclusions, and views expressed in this report do not necessarily represent the views of all experts.

Findings

Several Ontario experts were consulted, including family physicians, a hepatologist, and a hematologist. The experts agreed that the AST/ALT ratio can, in some cases, provide important information to help differentiate between types of liver damage, in particular when determining if the damage is alcohol related. However, the experts felt that ALT, the more specific liver test, should be the primary test used in community-based laboratories with access through hospitals to those specialists who require the additional information that AST may provide.
Conclusions

Based on the Ontario utilization data and expert consultations, there is inappropriate AST testing occurring in community laboratories in Ontario. Given the lack of specificity of AST compared to ALT, AST tests have limited utility in the community setting and testing should be restricted.
Acknowledgements

Editorial Staff
Pierre Lachaine